Cantor Fitzgerald Comments on Codexis FY2025 Earnings

Codexis, Inc. (NASDAQ:CDXS) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Codexis in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the biotechnology company will post earnings per share of ($0.51) for the year. Cantor Fitzgerald has a “Overweight” rating and a $11.00 price target on the stock. The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share.

Separately, Benchmark restated a “hold” rating on shares of Codexis in a research note on Monday, November 4th.

Codexis Price Performance

NASDAQ CDXS opened at $4.91 on Thursday. The stock has a market cap of $399.58 million, a price-to-earnings ratio of -5.64 and a beta of 2.13. Codexis has a 12 month low of $2.53 and a 12 month high of $6.08. The company’s 50 day moving average is $4.90 and its two-hundred day moving average is $3.80. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The company had revenue of $12.83 million during the quarter, compared to the consensus estimate of $11.64 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. During the same period last year, the business earned ($0.26) EPS.

Institutional Investors Weigh In On Codexis

A number of institutional investors have recently added to or reduced their stakes in CDXS. FMR LLC boosted its position in shares of Codexis by 1.2% during the third quarter. FMR LLC now owns 4,497,090 shares of the biotechnology company’s stock worth $13,851,000 after acquiring an additional 51,822 shares during the last quarter. Geode Capital Management LLC lifted its stake in Codexis by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,644,039 shares of the biotechnology company’s stock worth $5,065,000 after purchasing an additional 11,082 shares in the last quarter. State Street Corp boosted its holdings in shares of Codexis by 2.7% during the 3rd quarter. State Street Corp now owns 1,551,411 shares of the biotechnology company’s stock valued at $4,778,000 after purchasing an additional 41,480 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Codexis by 23.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,103,442 shares of the biotechnology company’s stock valued at $3,399,000 after purchasing an additional 209,207 shares during the last quarter. Finally, abrdn plc grew its position in shares of Codexis by 62.5% during the third quarter. abrdn plc now owns 800,410 shares of the biotechnology company’s stock valued at $2,465,000 after purchasing an additional 307,762 shares in the last quarter. 78.54% of the stock is owned by hedge funds and other institutional investors.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.